Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group HoldingsHKSE:06998 +0.33%15 EBITDA Margin % is 36.39% as of Dec. 2025, which is 1% below its 10-year median of 36.58. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 958 Drug Manufacturers companies, Edding Genor Group Holdings ranks better than 91.75% on this metric.
Edding Genor Group Holdings (HKSE:06998) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Edding Genor Group Holdings EBITDA Margin % Related Terms
Edding Genor Group Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings EBITDA Margin % Chart
Edding Genor Group Holdings Annual Data
Trend
Dec24
Dec25
EBITDA Margin %
36.77
36.39
Edding Genor Group Holdings Semi-Annual Data
Dec24
Dec25
EBITDA Margin %
36.77
36.39
HKSE:06998 vs ZTS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings (HKSE:06998) has a EBITDA Margin % of 36.39% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edding Genor Group Holdings and its competitors. This is near median its historical median of 36.58. Over the past decade, Edding Genor Group Holdings' EBITDA Margin % has ranged from 36.39 to 36.77. According to the industry distribution chart, Edding Genor Group Holdings ranks #79 out of 958 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Edding Genor Group Holdings' EBITDA Margin % too high?
Edding Genor Group Holdings' current EBITDA Margin % of 36.39% is near median its 10-year median of 36.58. Over the past 10 years, this metric has ranged from a low of 36.39 to a high of 36.77. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Edding Genor Group Holdings' value of 36.39% is 192.3% above this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #79 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #79 out of 958 companies for EBITDA Margin %. This places Edding Genor Group Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.45. Edding Genor Group Holdings' value of 36.39% is 192.3% above this benchmark. Historically, Edding Genor Group Holdings' own EBITDA Margin % has ranged from 36.39 to 36.77 over the past decade. While the company's 10-year median is 36.58 vs. the industry median of 12.45, Edding Genor Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current EBITDA Margin % of 36.39% is 192.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current EBITDA Margin % is 36.39%, which is near median its own 10-year median of 36.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current EBITDA Margin % of 36.39%. The current EBITDA Margin % is 36.39%, which is near median its 10-year median of 36.58 and 192.3% above the Drug Manufacturers industry median of 12.45. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current EBITDA Margin % is 36.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
